© The Author 2007. Published by Oxford University Press.
C-Reactive Protein and Risk of Breast Cancer
Affiliations of authors: Division of Preventive Medicine (SMZ, JL, NRC, IML, JEM, JEB, PMR), Channing Laboratory (JEM), Center for Cardiovascular Disease Prevention (NRC, JEB, PMR), and Donald W. Reynolds Center for Cardiovascular Research (NRC, JEB, PMR), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology, Harvard School of Public Health, Boston, MA (SMZ, NRC, IML, JEM, JEB, PMR); Department of Ambulatory Care and Prevention, Harvard Medical School, Boston, MA (JEB)
Correspondence to: Shumin M. Zhang, MD, ScD, Division of Preventive Medicine, Brigham and Women's Hospital, 900 Commonwealth Ave East, Boston, MA 02215 (e-mail: shumin.zhang{at}channing.harvard.edu).
Chronic inflammation is hypothesized to be associated with breast cancer development. However, data evaluating the association between C-reactive protein (CRP), a marker of systemic inflammation, and breast cancer risk are sparse. In the Women's Health Study, 27919 apparently healthy women aged 45 years and older who were free of cancer and cardiovascular disease had plasma CRP levels measured at baseline. During a mean of 10 years of follow-up, a total of 892 women developed invasive breast cancer. All statistical tests were two-sided. Baseline plasma CRP level was not statistically significantly associated with breast cancer risk (highest versus lowest quintile of CRP, multivariable hazard ratio = 0.90, 95% confidence interval = 0.71 to 1.16; Ptrend = .19; crude incidence rates: 273 versus 305 per 100000 person-years). Our data suggest that baseline plasma CRP levels are not associated with the increased risk of breast cancer in apparently healthy women.
| CONTEXT AND CAVEATS Prior knowledge Chronic inflammation might be associated with the development of breast cancer. C-reactive protein (CRP) is a marker of systemic inflammation. Study design Baseline plasma CRP levels were measured in healthy women aged 45 years and older, and the women were followed for 10 years for breast cancer incidence. Contribution No association between baseline plasma CRP levels and risk of invasive breast cancer was observed. Implications Baseline CRP levels are not associated with risk of breast cancer in healthy women. Study limitations Only a single measurement of plasma CRP was used in the study.
|
Manuscript received November 24, 2006; revised March 7, 2007; accepted April 6, 2007.
Correspondence about this Article
Related Article in JNCI
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2008 100: 443-444.
J Natl Cancer Inst 2007 99: 825.
This article has been cited by other articles:
|
|
 |
|
  A. Zeleniuch-Jacquotte, Y. Gu, P. F. Bruning, J. M.G. Bonfrer, K. L. Koenig, A. A. Arslan, P. Toniolo, and R. E. Shore Re: C-Reactive Protein and Risk of Breast Cancer J Natl Cancer Inst, March 19, 2008; 100(6): 443 - 444. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig, N. Khuseyinova, J. Baumert, and C. Meisinger Prospective Study of High-Sensitivity C-Reactive Protein as a Determinant of Mortality: Results from the MONICA/KORA Augsburg Cohort Study, 1984-1998 Clin. Chem., February 1, 2008; 54(2): 335 - 342. [Abstract] [Full Text] [PDF]
|
|